Bioavailability, Safety, and Tolerability of BIS-001 ER

• ClinicalTrials.gov Identifier: NCT03156439
• Recruitment Status: Completed
• First Posted: May 17, 2017
• Last Update Posted: January 18, 2018
• Sponsor: Supernus Pharmaceuticals, Inc.
• Collaborator: Melbourne Health
• Information provided by (Responsible Party): Supernus Pharmaceuticals, Inc.

Study Description

Brief Summary:

This study investigates the safety, tolerability, and pharmacokinetics of BIS-001 ER in healthy volunteers. Subjects will be dosed twice daily, with a dose escalation occurring every 2-3 days until a maximum dose of 5mg per day is reached.

Condition or disease	Intervention/treatment	Phase
Epilepsy, Complex Partial	Drug: BIS-001 ER	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 8 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Evaluation of the Bioavailability, Safety, and Tolerability of BIS-001 ER Following Multiple Dose Administration in Healthy Subjects
• Actual Study Start Date: May 22, 2017
• Actual Primary Completion Date: September 30, 2017
• Actual Study Completion Date: September 30, 2017

Arms and Interventions

Arm

Intervention/treatment

Experimental: BIS-001 ER; The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.

Drug: BIS-001 ER; BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.; Other Name: Huperzine A

Outcome Measures

Primary Outcome Measures :

1. Maximum serum concentration; Cmax [ Time Frame: 16 Weeks ]
   Bioavailability/Pharmacokinetic Assessments
2. Area under the curve; AUC [ Time Frame: 16 Weeks ]
   Bioavailability/Pharmacokinetic Assessments
3. Time of maximum serum concentration; Tmax [ Time Frame: 16 Weeks ]
   Bioavailability/Pharmacokinetic Assessments
4. Half-life; t1/2 [ Time Frame: 16 Weeks ]
   Bioavailability/Pharmacokinetic Assessments
5. Terminal elimination [ Time Frame: 16 Weeks ]
   Bioavailability/Pharmacokinetic Assessments
6. Clearance [ Time Frame: 16 Weeks ]
   Bioavailability/Pharmacokinetic Assessments
7. Volume of distribution [ Time Frame: 16 Weeks ]
   Bioavailability/Pharmacokinetic Assessments
8. Mean residence time [ Time Frame: 16 Weeks ]
   Bioavailability/Pharmacokinetic Assessments

Secondary Outcome Measures :

1. Safety and Tolerability Assessments - Adverse Events [ Time Frame: 16 Weeks ]
   Adverse events will be defined, documented, evaluated (mild/moderate/severe/life threatening; serious/non-serious; expected/unexpected; causally related to study drug or not) and reported according to all applicable institutional and governmental requirements and guidance.
2. Safety and Tolerability Assessments - Vital Signs [ Time Frame: 16 Weeks ]
   Vital signs (e.g. blood pressure) will be monitored through the first 8 hrs after drug administration, as well as at Baseline and pre-dose.
3. Safety and Tolerability Assessments - Neurological Evaluation [ Time Frame: 16 Weeks ]
   A standard neurological examination will be performed according to the study-specific timeline. Clinically significant new or worsened abnormalities as compared to baseline findings will have to be reported as AEs.
4. Safety and Tolerability Assessments - Physical Evaluation [ Time Frame: 16 Weeks ]
   A standard physical examination will be performed according to the study-specific timeline. Clinically significant new or worsened abnormalities as compared to baseline findings will have to be reported as AEs.
5. Safety and Tolerability Assessments - ECG Evaluation [ Time Frame: 16 Weeks ]

   A standard 12-lead ECG in a supine position after a 5-minute rest will be performed according to the study-specific timeline.

   The Investigator will determine whether the results of the ECG are normal or abnormal and assess the clinical significance of any abnormality. ECG tracings will be reviewed by a cardiologist if required.

6. Safety and Tolerability Assessments - Clinical Laboratory Studies: Hematology [ Time Frame: 16 Weeks ]
   Laboratory assessments will be conducted using standard methods.
7. Safety and Tolerability Assessments - Clinical Laboratory Studies: Biochemistry [ Time Frame: 16 Weeks ]
   Laboratory assessments will be conducted using standard methods.
8. Safety and Tolerability Assessments - Clinical Laboratory Studies: Urinalysis [ Time Frame: 16 Weeks ]
   Laboratory assessments will be conducted using standard methods.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 45 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Speak English with sufficient proficiency to read and comprehend the Informed Consent document, and to communicate with study staff.
2. Be able to consent to participate by signing the Informed Consent document after a full explanation of the nature and purpose of this study.
3. Have signed the Informed Consent before any study-specific procedures are performed
4. Be males or females between 18 - 45 years of age.
5. Have a negative urinary pregnancy test upon admission to the site on Day 1
6. Be in good general health in the judgment of the Principal Investigator based upon medical history, physical examination, standard 12-lead electrocardiogram (ECG), and clinical laboratory evaluations obtained within the two weeks prior to enrollment.
7. Be able to comply with all study-specified procedures.
8. Weight between 40 and 100 kg

Exclusion Criteria:

1. Has taken Huperzine A.
2. Is planning to become pregnant or impregnate spouse, not using an acceptable method of birth control (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant or nursing
3. Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder) or takes medications that, in the Principal Investigator's opinion, could interfere with the subject's suitability for participation in the study.
4. Has a history or evidence of significant psychiatric disturbance or illness, including alcohol or drug abuse within the past 2 years, or symptoms of psychosis (hallucinations, delusions) in the last 5 years.
5. Has had any clinical laboratory abnormalities within the past two months, prior to screening, considered of clinical significance by the Principal Investigator
6. Is on concomitant therapy with non-anti-epileptic drugs (AEDs) that are cholinergic.
7. Has participated in any clinical investigational drug or device study within four weeks prior to study entry.

Contacts and Locations

Locations

Australia, Victoria

The Royal Melbourne Hospital

Parkville, Victoria, Australia, 3050

Sponsors and Collaborators

Supernus Pharmaceuticals, Inc.

Melbourne Health

Investigators

• Study Chair: Stephen D Collins; President and CEO

More Information

• Responsible Party: Supernus Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT03156439
• Other Study ID Numbers: BNI-01-1b
• First Posted: May 17, 2017
• Last Update Posted: January 18, 2018
• Last Verified: January 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Epilepsy, Complex Partial; Epilepsy; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epilepsies, Partial; Huperzine A; Cholinesterase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Cholinergic Agents; Neurotransmitter Agents; Physiological Effects of Drugs; Neuroprotective Agents; Protective Agents